Atara Biotherapeutics Files 8-K on Exit Costs
Ticker: ATRA · Form: 8-K · Filed: Jan 27, 2025 · CIK: 1604464
| Field | Detail |
|---|---|
| Company | Atara Biotherapeutics, INC. (ATRA) |
| Form Type | 8-K |
| Filed Date | Jan 27, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $7.5 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: restructuring, disposal, financial-reporting
Related Tickers: ATRA
TL;DR
Atara Biotherapeutics filed an 8-K for exit/disposal costs. Details TBD.
AI Summary
On January 27, 2025, Atara Biotherapeutics, Inc. filed an 8-K report. The filing primarily concerns cost associated with exit or disposal activities and includes financial statements and exhibits. Specific details regarding the nature or financial impact of these activities are not elaborated in the provided text.
Why It Matters
This filing indicates Atara Biotherapeutics is undergoing restructuring or divesting certain operations, which could impact its future financial performance and strategic direction.
Risk Assessment
Risk Level: medium — Filings related to exit or disposal activities often signal significant operational changes or financial challenges that could affect the company's future.
Key Players & Entities
- Atara Biotherapeutics, Inc. (company) — Registrant
- January 27, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 001-36548 (filing_id) — SEC File Number
- 46-0920988 (tax_id) — IRS Employer Identification No.
- 2380 Conejo Spectrum Street Suite 200 (address) — Principal Executive Offices
- Thousand Oaks (city) — Principal Executive Offices City
- California (state) — Principal Executive Offices State
- 91320 (zip_code) — Principal Executive Offices Zip Code
- (805) 623-4211 (phone_number) — Registrant's Telephone Number
FAQ
What specific activities are associated with the 'Cost Associated with Exit or Disposal Activities' mentioned in the filing?
The provided text of the 8-K filing does not specify the exact nature or details of the exit or disposal activities.
When was the report filed with the SEC?
The report was filed on January 27, 2025.
What is the company's principal executive office address?
The company's principal executive office is located at 2380 Conejo Spectrum Street, Suite 200, Thousand Oaks, California, 91320.
What is the SEC file number for Atara Biotherapeutics, Inc.?
The SEC file number for Atara Biotherapeutics, Inc. is 001-36548.
What is the SIC code for Atara Biotherapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Atara Biotherapeutics, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 503 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2025-01-27 16:30:07
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ATRA The Nasdaq Stock Mar
- $7.5 million — pany expects to recognize approximately $7.5 million in total for severance and related bene
Filing Documents
- atra-20250127.htm (8-K) — 43KB
- 0000950170-25-009225.txt ( ) — 153KB
- atra-20250127.xsd (EX-101.SCH) — 24KB
- atra-20250127_htm.xml (XML) — 5KB
05 Costs Associated with Exit or Disposal Activities
Item 2.05 Costs Associated with Exit or Disposal Activities. On January 27, 2025, Atara Biotherapeutics, Inc. (the "Company") announced a reduction in its workforce that will impact approximately 50% of its current employees. The Company expects to substantially complete the workforce reduction by June 2025. The Company expects to recognize approximately $7.5 million in total for severance and related benefits for employees laid off under the reduction in force. These charges are primarily one-time termination benefits and are primarily cash charges. The Company may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the workforce reduction. Additional details will be provided in the Company's Quarterly Report on Form 10-Q for the period ending March 31, 2025.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Atara Biotherapeutics, Inc. Date: January 27, 2025 By: /s/ AnhCo Nguyen AnhCo Nguyen, Ph.D. President and Chief Executive Officer